Man Group plc purchased a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 108,761 shares of the company’s stock, valued at approximately $2,594,000. Man Group plc owned 0.36% of Castle Biosciences at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Global Retirement Partners LLC bought a new position in shares of Castle Biosciences in the second quarter worth $26,000. Federated Hermes Inc. bought a new position in Castle Biosciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Castle Biosciences in the 4th quarter valued at approximately $35,000. Jones Financial Companies Lllp lifted its holdings in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after acquiring an additional 976 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on CSTL shares. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. KeyCorp set a $35.00 price target on Castle Biosciences in a research note on Friday, May 29th. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. BTIG Research lifted their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences has a consensus rating of “Moderate Buy” and an average target price of $42.00.
Castle Biosciences Price Performance
Shares of CSTL opened at $33.03 on Tuesday. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.01 billion, a PE ratio of -50.05 and a beta of 0.98. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The business has a 50-day simple moving average of $27.48 and a two-hundred day simple moving average of $25.43.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Castle Biosciences news, insider Derek J. Maetzold sold 2,546 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $30.68, for a total transaction of $78,111.28. Following the sale, the insider directly owned 21,479 shares of the company’s stock, valued at $658,975.72. The trade was a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin W. Juvenal sold 9,050 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total transaction of $317,112.00. Following the completion of the transaction, the insider owned 66,914 shares of the company’s stock, valued at approximately $2,344,666.56. This trade represents a 11.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 169,957 shares of company stock worth $4,996,708 in the last ninety days. Company insiders own 6.10% of the company’s stock.
Castle Biosciences Company Profile
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Featured Stories
- Five stocks we like better than Castle Biosciences
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report).
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
